Medifast, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Nicholas Johnson
- Full Time Employees
- 380
- Sector
- Industrials
- Industry
- Personal Products & Services
- Address
- 1501 S. Clinton Street Baltimore MD United States of America 21224
- IPO Date
- Dec 30, 1993
- CIK
- 0000910329
- Website
- medifastinc.com
- Similar Companies
- Business
- Medifast, Inc. Medifast, Inc. (NYSE: MED) operates as a health and wellness company that develops, manufactures, and sells clinically proven nutrition products and coach-guided lifestyle programs primarily through its OPTAVIA brand; core offerings include portion-controlled meal replacements such as bars, shakes, soups, puddings, oatmeal, pancakes, smoothies, and soft bakes, alongside the 5 & 1 Plan featuring Lean & Green meals, the Habits of Health Transformational System, and specialized lines like OPTAVIA ACTIVE for muscle health with Essential Amino Acid Blends and whey protein, and OPTAVIA ASCEND high-protein mini meals and nutrient packs tailored for GLP-1 medication users and weight maintenance. Products reach customers via a network of independent OPTAVIA Coaches using direct sales, e-commerce, and community support, targeting consumers seeking weight management, metabolic health, and lifelong healthy habits in the United States weight management market. Founded in 1980 and headquartered in Baltimore, Maryland, the company conducts operations mainly in the U.S. with over 40 years of experience, subsidiaries including Optavia (formerly Take Shape for Life), Jason Pharmaceuticals, and recent innovations backed by a Scientific Advisory Board. Recent developments encompass the 2024 launch of OPTAVIA ASCEND to address gaps in GLP-1 support and muscle preservation, an ongoing collaboration with LifeMD providing coach clients access to clinicians and GLP-1 medications including joint marketing pilots, a planned 2025 program with new OPTAVIA ASCEND products and a clinical study on integrated nutrition-lifestyle outcomes, and optimized marketing spend reductions to $20-25 million for 2024 while enhancing coach productivity amid revenue adjustments.
Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround?
MED Rallies 13.6% in the Past Month: Can the Momentum Keep Building?
Can MED's Trilivy Launch and Cost Cuts Drive a Q4 Profit Turnaround?
Medifast: Worth A Speculative Entry As Sales Stabilize (Rating Upgrade)
Medifast Q2 Loss Narrower Than Expected, Coach Productivity Improves
Medifast, Inc. (MED) Q2 2026 Earnings Call Transcript
Medifast Q2 Earnings Call Highlights
Medifast (MED) Reports Q2 Loss, Beats Revenue Estimates
Medifast Announces Second Quarter 2026 Financial Results
Medifast Stock to Post Q2 Earnings: What Investors Should Know
Medifast (MED) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Medifast to Announce Financial Results for the Second Quarter Ended June 30, 2026
Will Medifast's Trilivy Launch Unlock a New Growth Chapter?
Medifast® Enters a New Era: Introducing Trilivy™, a Science-Backed Metabolic Health System
Medifast (MED) Loses 18.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management
What Science-Backed Subscription Health Programs Measure Differently
Medifast (MED) Down 5.1% Since Last Earnings Report: Can It Rebound?
Is MEDIFAST (MED) Stock Outpacing Its Consumer Staples Peers This Year?
Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer